|
- 2019
Original research article: High incidence of atrial fibrillation in patients treated with ibrutinibDOI: 10.1136/openhrt-2019-001049 Keywords: atrial fibrillation, cardio-oncology, cardiotoxicity, ibrutinib Abstract: Atrial fibrillation (AF) is one of the most common side effects of ibrutinib, a drug that has dramatically improved the prognosis of chronic B-cell malignancies such as chronic lymphocytic leukaemia (CLL). The true incidence of ibrutinib-related AF (IRAF) is not well known and its therapeutic management poses unique challenges especially due to the inherent risk of bleeding. We aimed to determine the incidence and predictors of IRAF, and to analyse its management and outcome
|